نتایج جستجو برای: facit

تعداد نتایج: 404  

Journal: :The European Journal of Development Research 2021

In this paper, we discuss the challenges and opportunities faced by developing countries that want to join so-called Fourth Industrial Revolution (4IR). We first point out current discourse on 4IR is often based poor understanding of true nature phenomenon. Emphasising many technologies have been there evolving rapidly in last half a century, argue what defines fusion these technologies. Given ...

Journal: :Integrative cancer therapies 2015
Rachel Jolliffe Helen Seers Sarah Jackson Elena Caro Laura Weeks Marie J Polley

OBJECTIVE Measure Yourself Concerns and Wellbeing (MYCaW) is a patient-centered questionnaire that allows cancer patients to identify and quantify the severity of their "concerns" and "wellbeing," as opposed to using a predetermined list. MYCaW administration is brief and aids in prioritizing treatment approaches. Our goal was to assess the convergent validity and responsiveness of MYCaW scores...

2015
Frits van Rhee Margaret Rothman Kai Fai Ho Sarah Fleming Raymond S. Wong Alexander Fosså Angela Dispenzieri James Cavet Nikhil Munshi Jessica Vermeulen Corey Casper

BACKGROUND Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder driven by dysregulated interleukin-6 production. MCD has a poor prognosis, and treatment is generally noncurative and aimed at symptom relief. Siltuximab is a novel, monoclonal interleukin-6 antibody recently shown to be effective in a registration clinical trial. MCD symptoms, such as fatigue, pain, and we...

2011
Vibeke Strand Anne M. Rentz Mary A. Cifaldi Naijun Chen Sanjoy Roy VIBEKE STRAND ANNE M. RENTZ MARY A. CIFALDI NAIJUN CHEN

Objective. Rheumatoid arthritis (RA) is associated with significant impairments in health-related quality of life (HRQOL). We evaluated patient-reported outcomes including HRQOL outcomes following adalimumab plus methotrexate (MTX) therapy in patients with early RA. Methods. PREMIER was a phase III, multicenter, randomized, double-blind, active-comparator clinical trial in early RA. Patients ag...

Journal: :Journal of the American College of Surgeons 2012
Theresa P Yeo Sherry A Burrell Patricia K Sauter Eugene P Kennedy Harish Lavu Benjamin E Leiby Charles J Yeo

BACKGROUND As patients with pancreas and periampullary cancer (PPC) experience improved survival rates and longevity, the focus shifts toward living life while surviving cancer. Fatigue is the most commonly reported symptom in all cancer patients. Exercise has been found to effectively decrease fatigue levels and improve physical functioning in cancer patients. STUDY DESIGN One hundred two pa...

Journal: :Tumori 2012
Carla Ida Ripamonti Loredana Buonaccorso Alice Maruelli Elena Bandieri Stefania Boldini Maria Adelaide Pessi Francesca Chiesi Guido Miccinesi

AIMS AND BACKGROUND Although hope is a widely used term, the experience of hope in patients with chronic or even life-threatening diseases is often disregarded due to the scarcity of carefully designed and validated assessment tools. The aim of this study was to validate the Hope Herth Index (HHI) questionnaire in the Italian population of patients with solid or hematological malignancies durin...

2015
Paul Emery Arthur Kavanaugh Yanjun Bao Arijit Ganguli Parvez Mulani

BACKGROUND This study assessed the impact of simultaneous achievement of clinical, functional and structural efficacy, herein referred to as comprehensive disease control (CDC), on short-term and long-term work-related outcomes, health-related quality of life (HRQoL), pain and fatigue. METHODS Data were pooled from three randomised trials of adalimumab plus methotrexate for treatment of early...

2016
Atul A. Deodhar Maxime Dougados Dominique L. Baeten James Cheng‐Chung Wei Piet Geusens Aimee Readie Hanno B. Richards Ruvie Martin Brian Porter

OBJECTIVE To evaluate the effect of secukinumab (interleukin-17A inhibitor) on patient-reported outcomes in patients with active ankylosing spondylitis (AS). METHODS In this phase III study, 371 patients were randomized (1:1:1) to receive intravenous (IV) secukinumab 10 mg/kg at baseline and weeks 2 and 4 followed by subcutaneous (SC) secukinumab 150 mg every 4 weeks (IV→150 mg group), or SC ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید